• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[从外科角度看局部晚期食管癌肿瘤治疗中的当前术前和围手术期概念]

[Current preoperative and perioperative concepts in tumor treatment for locally advanced esophageal carcinoma from a surgical perspective].

作者信息

Hoeppner Jens

机构信息

Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.

出版信息

Chirurg. 2021 Dec;92(12):1094-1099. doi: 10.1007/s00104-021-01475-w. Epub 2021 Aug 13.

DOI:10.1007/s00104-021-01475-w
PMID:34387699
Abstract

Locally advanced esophageal cancer is mostly treated in multimodal therapy protocols according to the current western treatment guidelines. In squamous cell cancer, neoadjuvant chemoradiotherapy is in the foreground. Unimodal surgical and chemoradiation treatment alternatives achieve poorer results for this entity. Surgical salvage resection for tumor recurrence after definitive chemoradiotherapy can be carried out with good oncological results but the frequency of postoperative complications is increased. For locally advanced adenocarcinoma of the esophagus, perioperative chemotherapy and neoadjuvant chemoradiotherapy are two competing level 1 evidence-based treatment concepts that are superior to treatment by surgery alone. The results of head-to-head comparative treatment studies are still pending. A significant number of patients show a complete locoregional remission of the tumor in the surgical specimen after treatment with the modern neoadjuvant protocols. Currently, European prospective randomized noninferiority studies with an oncological endpoint are testing the possibilities of organ-retaining concepts in clinical complete remission (surgery as needed; watch and wait). For the future, it is to be expected that the curative treatment results of locally advanced esophageal carcinoma will again significantly improve, in particular through the additional possibilities of immunotherapy and organ-preserving therapy concepts for postneoadjuvant complete remission.

摘要

根据当前西方治疗指南,局部晚期食管癌大多采用多模式治疗方案。在鳞状细胞癌中,新辅助放化疗处于前沿。对于该类型癌症,单一的手术和放化疗替代方案效果较差。根治性放化疗后肿瘤复发的手术挽救性切除可以取得良好的肿瘤学效果,但术后并发症的发生率会增加。对于局部晚期食管腺癌,围手术期化疗和新辅助放化疗是两种相互竞争的1级循证治疗理念,均优于单纯手术治疗。头对头比较治疗研究的结果仍未可知。相当数量的患者在接受现代新辅助方案治疗后,手术标本中的肿瘤出现完全局部区域缓解。目前,欧洲以肿瘤学为终点的前瞻性随机非劣效性研究正在测试临床完全缓解时保留器官理念的可能性(按需手术;观察等待)。展望未来,预计局部晚期食管癌的根治性治疗效果将再次显著改善,特别是通过免疫治疗以及新辅助后完全缓解时保留器官治疗理念带来的更多可能性。

相似文献

1
[Current preoperative and perioperative concepts in tumor treatment for locally advanced esophageal carcinoma from a surgical perspective].[从外科角度看局部晚期食管癌肿瘤治疗中的当前术前和围手术期概念]
Chirurg. 2021 Dec;92(12):1094-1099. doi: 10.1007/s00104-021-01475-w. Epub 2021 Aug 13.
2
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).ESOPEC:一项前瞻性随机对照多中心III期试验,比较围手术期化疗(FLOT方案)与新辅助放化疗(CROSS方案)用于食管癌患者(NCT02509286)。
BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.
3
[Complete response after neoadjuvant therapy for esophageal cancer : Implications for surgery].[食管癌新辅助治疗后的完全缓解:对手术的影响]
Chirurg. 2022 Feb;93(2):132-137. doi: 10.1007/s00104-021-01509-3. Epub 2021 Oct 1.
4
[Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer?].[新辅助放化疗还是化疗用于局部晚期食管癌?]
Chirurg. 2020 May;91(5):379-383. doi: 10.1007/s00104-020-01150-6.
5
CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cTNM) (NCT03001596).CMISG1701:一项多中心前瞻性随机III期临床试验,比较新辅助放化疗与新辅助化疗后行微创食管切除术在局部晚期可切除食管鳞状细胞癌(cTNM)患者中的疗效(NCT03001596)。
BMC Cancer. 2017 Jun 28;17(1):450. doi: 10.1186/s12885-017-3446-7.
6
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).新辅助放化疗后手术与单纯手术治疗食管腺癌或鳞癌患者的比较(CROSS研究)
BMC Surg. 2008 Nov 26;8:21. doi: 10.1186/1471-2482-8-21.
7
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.比较局部进展期胃癌或食管胃结合部腺癌患者术前放化疗与术前化疗的随机 III 期临床试验方案:PREACT。
BMC Cancer. 2019 Jun 20;19(1):606. doi: 10.1186/s12885-019-5728-8.
8
[Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].[食管癌挽救性手术:根治性放化疗(>50 Gy)后患者的可行性]
Chirurg. 2015 Oct;86(10):955-62. doi: 10.1007/s00104-014-2971-z.
9
Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.局部晚期食管腺癌的多模态治疗:我们应该选择哪种方案?105 例患者围手术期化疗与新辅助放化疗的疗效分析。
J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498. Epub 2013 Nov 26.
10
[Surgical strategy in multimodal treatment of gastric and esophageal cancer].[胃癌和食管癌多模式治疗中的手术策略]
Chirurg. 2017 Dec;88(12):1005-1009. doi: 10.1007/s00104-017-0545-6.

本文引用的文献

1
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.曲美木单抗与度伐利尤单抗联合用于微卫星高度不稳定(MSI-H)可切除胃癌或胃食管交界癌的非手术治疗(NOM):多中心、单臂、多队列II期INFINITY研究
Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839.
2
Definitive Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy With Esophagectomy for Locoregional Esophageal Cancer: National Population-based Cohort Study.局部区域性食管癌的根治性放化疗与新辅助放化疗加手术治疗的比较:全国基于人群的队列研究。
Ann Surg. 2022 Mar 1;275(3):526-533. doi: 10.1097/SLA.0000000000003941.
3
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.KEYNOTE-585:帕博利珠单抗联合或不联合围手术期化疗用于胃癌的 III 期研究。
Future Oncol. 2019 Mar;15(9):943-952. doi: 10.2217/fon-2018-0581. Epub 2019 Feb 19.
4
Laparoscopic versus open gastrectomy for gastric cancer.腹腔镜与开腹胃癌切除术对比
Cochrane Database Syst Rev. 2016 Mar 31;3(3):CD011389. doi: 10.1002/14651858.CD011389.pub2.
5
Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.局部晚期食管腺癌的多模态治疗:我们应该选择哪种方案?105 例患者围手术期化疗与新辅助放化疗的疗效分析。
J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498. Epub 2013 Nov 26.
6
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.可切除的胃食管癌围手术期化疗与单纯手术治疗的比较
N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531.